Syntara (SNT) Investor presentation summary

Investment highlights and financial position

• Clinical-stage drug developer with a diversified pipeline in blood cancers, fibrosis, and neurodegenerative diseases, backed by 44% institutional investors and $13.5m cash, funded into FY28.

• Three Phase 2 studies in blood cancer indications with addressable market value over $4.5bn and $11.5m in non-dilutive grant funding in the last three years.

• Market cap of A$47m and enterprise value of A$33.5m as of July 2026, with significant research coverage.

Pipeline and clinical development

• Lead asset amsulostat is a first-in-class pan-LOX inhibitor with orphan drug designation for myelofibrosis, showing strong safety and efficacy in Phase 2a trials.

• Additional assets include SNT-9465 for fibrosis/skin scarring and SNT-4728 for Parkinson's/iRBD, both advancing through clinical stages.

• Amsulostat demonstrated a differentiated safety profile, with no treatment-related serious adverse events and favorable tolerability as an add-on to JAK inhibitors.

Clinical results and market opportunity

• In myelofibrosis, 73% of patients achieved ≥50% symptom reduction at 24 weeks, and 44% achieved significant spleen volume reduction.

• Amsulostat's mechanism targets fibrosis and microenvironmental signaling, supporting potential for disease modification and earlier-stage use.

• Strong strategic interest in myelofibrosis assets, with recent deals in the sector reaching up to $2.9bn.